Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Jackson

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Neoplasia (New York, N.Y.)|November 25, 2017
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid LeukemiaCathy C Zhang, Zhengming Yan, Bernadette Pascual, et al.
Investigational New Drugs|May 22, 2026
A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancerFengting Yan, Marcia Cruz-Correa, Jennifer Specht, et al.
Environmental Science and Pollution Research International|June 15, 2017
Chemical and microbial characteristics of municipal drinking water supply systems in the Canadian ArcticKiley Daley, Lisbeth Truelstrup Hansen, Rob C Jamieson, et al.
Translational Behavioral Medicine|April 21, 2023
Anticipating adaptation: tracking the impact of planned and unplanned adaptations during the implementation of a complex population-based genomic screening programCaitlin G Allen, Daniel P Judge, Paul J Nietert, et al.
American Journal of Human Genetics|February 2, 2024
Using implementation science to evaluate a population-wide genomic screening program: Findings from the first 20,000 In Our DNA SC participantsCaitlin G Allen, Kelly J Hunt, Lori L McMahon, et al.
Journal of Personalized Medicine|August 26, 2022
Lessons Learned from the Pilot Phase of a Population-Wide Genomic Screening Program: Building the Base to Reach a Diverse Cohort of 100,000 ParticipantsCaitlin G Allen, Leslie Lenert, Kelly Hunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L Maitland, Jasgit C Sachdev, Manish R Sharma, et al.
Plos One|July 5, 2013
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA MutationDouglas D Fang, Cathy C Zhang, Yin Gu, et al.
Journal of Translational Medicine|April 19, 2015
GLI2 inhibition abrogates human leukemia stem cell dormancyAnil Sadarangani, Gabriel Pineda, Kathleen M Lennon, et al.
Molecular Cancer Therapeutics|May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint TherapiesKeith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Neoplasia (New York, N.Y.)|November 25, 2017
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid LeukemiaCathy C Zhang, Zhengming Yan, Bernadette Pascual, et al.
Investigational New Drugs|May 22, 2026
A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancerFengting Yan, Marcia Cruz-Correa, Jennifer Specht, et al.
Environmental Science and Pollution Research International|June 15, 2017
Chemical and microbial characteristics of municipal drinking water supply systems in the Canadian ArcticKiley Daley, Lisbeth Truelstrup Hansen, Rob C Jamieson, et al.
Translational Behavioral Medicine|April 21, 2023
Anticipating adaptation: tracking the impact of planned and unplanned adaptations during the implementation of a complex population-based genomic screening programCaitlin G Allen, Daniel P Judge, Paul J Nietert, et al.
American Journal of Human Genetics|February 2, 2024
Using implementation science to evaluate a population-wide genomic screening program: Findings from the first 20,000 In Our DNA SC participantsCaitlin G Allen, Kelly J Hunt, Lori L McMahon, et al.
Journal of Personalized Medicine|August 26, 2022
Lessons Learned from the Pilot Phase of a Population-Wide Genomic Screening Program: Building the Base to Reach a Diverse Cohort of 100,000 ParticipantsCaitlin G Allen, Leslie Lenert, Kelly Hunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L Maitland, Jasgit C Sachdev, Manish R Sharma, et al.
Plos One|July 5, 2013
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA MutationDouglas D Fang, Cathy C Zhang, Yin Gu, et al.
Journal of Translational Medicine|April 19, 2015
GLI2 inhibition abrogates human leukemia stem cell dormancyAnil Sadarangani, Gabriel Pineda, Kathleen M Lennon, et al.
Molecular Cancer Therapeutics|May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint TherapiesKeith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
Pageof 5